A Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone on Carotid Intima-Media Thickness in Nondiabetic Hemodialysis Patients

Antonio Vukusich, S Kunstmann, Cristián Varela, Daniela Gainza, Sebastián Bravo, Daniela Sepúlveda, Gabriel Cavada, Luis Michea, Elisa T. Marusic

Clinical Journal of the American Society of Nephrology · 2010 · 93 citations · 23 references

DOIFull text

Open access

Abstract

Fifty milligrams of spironolactone thrice weekly significantly reduced the progression of CIMT in HD patients.

References

23